X4 Pharmaceuticals Inc Post-EHA Corporate Update Transcript
Greetings and welcome to X4 Pharmaceuticals Post-EHA Corporate Update Conference Call. (Operator Instructions) As a reminder, this conference call is being recorded.
It is now my pleasure to introduce your host, Candice Ellis, Director of Corporate Communications and Investor Relations at X4. You may begin.
Thank you, Andrew, and good morning everyone. Thanks so much for joining us as we discuss the positive clinical data on our lead candidate, mavorixafor, in patients with WHIM syndrome which was presented virtually earlier this morning at the 25th European Hematology Association or EHA Annual Congress.
As a reminder, we'll be making forward-looking statements regarding our regulatory and product development plan as well as our research activities. These statements are subject to risks and uncertainties that may cause actual results to differ from those forecasted. A description of these risks can be found in our most recent Form 10-K on file with the SEC.
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |